SSR-180,711

SSR-180,711

SSR-180,711
Systematic (IUPAC) name
(4-bromophenyl) 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate
Clinical data
Legal status
?
Identifiers
ATC code ?
PubChem
Chemical data
Formula C14H21BrN2O2 
Mol. mass 329.232
 YesY   

SSR180711 is a drug that acts as a potent and selective partial agonist for the α7 subtype of neural nicotinic acetylcholine receptors.[1][2] In animal studies, it shows nootropic effects and may be useful in the treatment of schizophrenia.[3][4]

References

  1. ^ Pichat, P.; Bergis, O.; Terranova, J.; Urani, A.; Duarte, C.; Santucci, V.; Gueudet, C.; Voltz, C.; Steinberg, R.; Stemmelin, J.; Oury-Donat, F.; Avenet, P.; Griebel, G.; Scatton, B. (2007). "SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia". Neuropsychopharmacology 32 (1): 17–34.  
  2. ^ Biton, B.; Bergis, O.; Galli, F.; Nedelec, A.; Lochead, A.; Jegham, S.; Godet, D.; Lanneau, C.; Santamaria, R.; Chesney, F. O.; Léonardon, J.; Granger, P.; Debono, M. W.; Bohme, G. A.; Sgard, F. D. R.; Besnard, F. O.; Graham, D.; Coste, A.; Oblin, A.; Curet, O.; Vigé, X.; Voltz, C.; Rouquier, L.; Souilhac, J.; Santucci, V.; Gueudet, C.; Françon, D.; Steinberg, R. G.; Griebel, G.; Oury-Donat, F. (2007). "SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile". Neuropsychopharmacology 32 (1): 1–16.  
  3. ^ Hashimoto, K.; Ishima, T.; Fujita, Y.; Matsuo, M.; Kobashi, T.; Takahagi, M.; Tsukada, H.; Iyo, M. (2008). "Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective alpha7 nicotinic receptor agonist SSR180711". Biological Psychiatry 63 (1): 92–97.  
  4. ^ Barak, S.; Arad, M.; De Levie, A.; Black, M.; Griebel, G.; Weiner, I. (2009). "Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia". Neuropsychopharmacology 34 (7): 1753–1763.